Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

Running, not enrolling · Phase 3

Conditions studied: High-risk Large B-cell Lymphoma (LBCL)

In brief

The goal of this clinical study is to compare the study drug, axicabtagene ciloleucel, versus standard of care (SOC) in first-line therapy in participants with high-risk large B-cell lymphoma.

Key facts

Study ID
NCT05605899
Run by
Kite, A Gilead Company
People needed
300
Starts
2023-02-10
Expected to finish
2031-03-01
Last updated by the study team
2026-04-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.